Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 3/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680778 | 0.90 | F10 (0.41) | F10ALOX5APFEN1 | |
| SCHEMBL6990369 | 0.79 | F10 (0.33) | ADORA2AADORA1F10ALOX5APFEN1 | |
| SCHEMBL6980798 | 0.77 | LOXL2 (0.33) | F10 | |
| SCHEMBL6989413 | 0.75 | ALOX5AP (0.33) | F10ALOX5APFEN1EGLN1 | |
| SCHEMBL6614516 | 0.74 | LOXL2 (0.37) | ADORA2AADORA1F10ALOX5APFEN1 | |
| SCHEMBL6990707 | 0.74 | F10 (0.40) | F10ALOX5APFEN1 | |
| SCHEMBL6985337 | 0.73 | LMNA (0.40) | F10ALOX5APFEN1 | |
| SCHEMBL4680194 | 0.70 | F10 (0.42) | F10ALOX5APFEN1 | |
| SCHEMBL6989555 | 0.68 | F10 (0.43) | F10 | |
| SCHEMBL6985663 | 0.68 | F10 (0.45) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337251-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002102380-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |